Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jeffrey Bluestone also recently made the following trade(s):

• On Friday, November 28th, Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock. The stock was sold at an average price of $125.08, for a total value of $625,400.00.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $131.14 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company’s 50-day moving average price is $123.76 and its 200 day moving average price is $118.46. Gilead Sciences, Inc. has a 52 week low of $92.21 and a 52 week high of $133.10. The stock has a market cap of $162.70 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 0.68 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GILD shares. Truist Financial began coverage on shares of Gilead Sciences in a report on Monday, November 24th. They set a “buy” rating and a $140.00 price target for the company. Wells Fargo & Company increased their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Royal Bank Of Canada increased their target price on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Finally, UBS Group reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.52.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors have recently bought and sold shares of the business. Csenge Advisory Group grew its position in shares of Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 16,288 shares during the period. Railway Pension Investments Ltd lifted its holdings in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after buying an additional 42,200 shares during the period. TriaGen Wealth Management LLC bought a new position in Gilead Sciences in the third quarter valued at approximately $1,274,000. Invesco Ltd. grew its holdings in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Finally, Sivik Global Healthcare LLC grew its holdings in Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after acquiring an additional 10,000 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT‑04/KEYNOTE‑D19 results showing Trodelvy (sacituzumab govitecan) + Keytruda met the primary endpoint with a ~35% PFS improvement (HR 0.65), supporting the combo as a potential new first‑line standard in PD‑L1+ metastatic TNBC — a major commercial catalyst for Gilead’s oncology franchise. NEJM ASCENT-04 Results
• Positive Sentiment: Multiple outlets (PharmaLetter) summarized the NEJM publication and reinforced the significance of the clinical data for Trodelvy’s uptake and reimbursement discussions — amplifying the immediate market reaction. PharmaLetter Trodelvy-Keytruda NEJM Coverage
• Positive Sentiment: Rothschild & Co Redburn raised its price target to $159 and kept a “buy” rating — a bullish institutional signal that supports further upside and likely contributed to buying momentum. Rothschild & Co Redburn Price Target
• Positive Sentiment: Investor commentary highlighting margin expansion and stronger free cash flow as underappreciated drivers has supported fundamental buying beyond the clinical news. Seeking Alpha on Margins & Cash Flow
• Neutral Sentiment: Market write‑ups and a Zacks note pointed out that GILD outpaced the broader market today — useful for context but largely descriptive of price action rather than new fundamental change. Zacks: Why GILD Outpaced Market
• Neutral Sentiment: Valuation and technical pieces note recent share‑price strength and improved momentum — these can attract traders but don’t alter the clinical/commercial thesis. Yahoo Valuation Check
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at ~$123.50), reducing his stake by ~36% — an insider sale that can prompt short‑term investor concern about timing or confidence (though insiders sell for many non‑signal reasons). SEC Form 4 — Bluestone
• Negative Sentiment: RBC’s price target (~$103, sector perform) remains well below current levels — a conservative analyst view that could limit upside if other firms adopt similar stances. RBC Price Target Note

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.